Prima BioMed announces that the submission titled “LAG-3Ig (IMP321) in combination with anti-PD-1 therapy” has been accepted for a presentation at the Society for Immunotherapy of Cancer’s New Cancer Immunotherapy Agents in Development program.

Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima”) announces that the submission titled “LAG-3Ig (IMP321) in combination with anti-PD-1 therapy” has been accepted for a presentation at the Society for Immunotherapy of Cancer (SITC)’s New Cancer Immunotherapy Agents in Development program.
This program, which is part of SITC 2016, is being held on Wednesday, November 9, 2016 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Dr Frédéric Triebel, Prima’s Chief Medical & Scientific Officer, will deliver the presentation between 11:10am and 12:20pm.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

For further information, please contact:
Australia Investor/Media:
Mr. Matthew Gregorowski
Citadel-MAGNUS
+61 (2) 8234 0100
mgregorowski@citadelmagnus.com
U.S. Investors:
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
mbeck@troutgroup.com